Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
Read our latest update

US Bioservices now dispenses XOSPATA® (gilteritinib)

June 17, 2020

XOSPATA® is an oral once-daily kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.